+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-Hodgkin lymphoma treatment Market 2019-2025

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129877
UP TO OFF until Dec 31st 2022
Global Non-Hodgkin lymphoma treatment Market Size, Share & Trends Analysis Report By Cell Type (B-Cell and T-Cell), By Therapy Type (Chemotherapy, Radiation Therapy, and Others), and Forecast 2019-2025.

The global Non-Hodgkin lymphoma treatment market is anticipated to grow significantly during the forecast period. Non-Hodgkin lymphoma originates from the white blood cell and affects the parts of the body’s immune system. Treatment of Non-Hodgkin lymphoma depends on the several factors such as age, type of Non-Hodgkin lymphoma, and stage of Non-Hodgkin lymphoma. The factor such as increasing R&D activities in therapeutics drugs industry coupled with the increasing prevalence of Non-Hodgkin lymphoma disease will drive Non-Hodgkin lymphoma treatment market. According to Cancer Research UK in 2017, around 14,100 new non-Hodgkin lymphoma cases are registered every year in the UK.

The global Non-Hodgkin lymphoma treatment market is segmented on the basis of Cell type and therapy type. Based on cell type, the market is bifurcated into B-Cell lymphoma and T-Cell lymphoma. The treatment of B-cell Non-Hodgkin lymphoma is mainly based on the subtype and stage of the disease. In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell Non-Hodgkin lymphoma. Based on the therapy type, the market is sub-segmented into immunotherapy, chemotherapy, targeted therapy, radiation, and stem cell transplant.

Geographically, the study of the global Non-Hodgkin lymphoma treatment market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. North America is estimated to contribute a significant share in the market during the forecast period. Asia-Pacific is estimated to exhibit a significant growth rate in the global Non-Hodgkin lymphoma treatment market during the forecast period.

Moreover, the study of the global Non-Hodgkin lymphoma treatment market report covers the analysis of various players operating in the market. Some of the key players covered in the report include AbbVie Inc., AstraZeneca PLC, Novartis International AG, Seattle Genetics, Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Merck & Co., Inc., Bayer AG, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by adopting various strategies to stay competitive in the market.

Research Methodology

The market study of the Non-Hodgkin lymphoma treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for working in Lymphoma landscape, pharmaceutical companies, drug manufacturers, medical device companies, healthcare industry, research organizations, academic institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis by Cell Type
2. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis by Therapy Type

The Report Covers
  • Comprehensive research methodology of the Non-Hodgkin lymphoma treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Non-Hodgkin lymphoma treatment market.
  • Insights about market determinants which are stimulating the Non-Hodgkin lymphoma treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Strategy Analysis
3.2. Key Company Analysis
3.2.1. AbbVie Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.2. AstraZeneca PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.2.3. Seattle Genetics Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.4. Teva Pharmaceuticals Industries Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.2.5. Novartis International AG Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Non-Hodgkin Lymphoma Treatment Market by Cell Type
5.1.1. B-Cell
5.1.2. T-Cell
5.2. Non-Hodgkin Lymphoma Treatment Market by Therapy Type
5.2.1. Chemotherapy
5.2.2. Radiation Therapy
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Amgen Inc.
7.3. AstraZeneca PLC
7.4. Bayer AG
7.5. Bristol Myers Squibb Co.
7.6. Eli Lilly and Co.
7.7. Epizyme, Inc.
7.8. F. Hoffmann-La Roche Ltd.
7.9. Gilead Sciences, Inc.
7.10. GlaxoSmithKline PLC
7.11. Johnson & Johnson Services Inc.
7.12. Merck & Co., Inc.
7.13. Nordic Nanovector ASA
7.14. Novartis International AG
7.15. Pfizer Inc.
7.16. Sanofi SA
7.17. Seattle Genetics, Inc.
7.18. Sorrento Therapeutics, Inc.
7.19. Spectrum Pharmaceuticals, Inc.
7.20. Takeda Pharmaceutical Co. Ltd.
7.21. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • Epizyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Nordic Nanovector ASA
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Seattle Genetics, Inc.
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.